Francesco C.
- Country
- Italy
- Department
- U.O. di Oncologia
Research Overview
- C5731001 - An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
- Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials
- Evaluation of Safety and Efficacy of XL092 with Nivolumab, Ipilimumab, and Relatlimab in Advanced or Metastatic Solid Tumors
Data & Insights
Has run more than one trial at 118 of 275 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating advanced urothelial carcinoma and metastatic renal cell carcinoma, with particular focus on innovative immunotherapy combinations and targeted treatments.
- HER2-expressing urothelial cancer management
- Advanced bladder cancer immunotherapy
- Renal cell carcinoma treatment strategies
Research interests extend to novel therapeutic approaches using checkpoint inhibitors and targeted agents for urological cancers.
Prostate Cancer Research
Focuses on developing treatments for high-risk nonmetastatic prostate cancer and metastatic castration-resistant prostate cancer, exploring hormone therapy combinations.
- Hormone therapy optimization
- Novel therapeutic combinations
- Long-term treatment outcomes
Investigates innovative treatment approaches for various stages of prostate cancer progression.
Breast Cancer Studies
Conducts research in metastatic triple-negative breast cancer and endocrine-responsive early breast cancer, focusing on combination therapy approaches.
- Triple-negative breast cancer treatment
- Immunotherapy combinations
- Endocrine therapy optimization
Explores innovative treatment sequences and combinations for different breast cancer subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.